RDHL
Redhill Biopharma Ltd
NASDAQ: RDHL · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC
$0.43
-4.49% today
Updated 2026-10-28
Market cap
$3.75M
P/E ratio
—
P/S ratio
10.21x
EPS (TTM)
$0.00
Dividend yield
—
52W range
$0 – $2
Volume
2.6M
WallStSmart proprietary scores
34
out of 100
Grade: F
Strong Sell
Investment rating
5.3
Growth
C+4.5
Quality
C3.0
Profitability
D5.0
Valuation
C+3/9
Piotroski F-Score
Weak
-24.4
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →270 stocks currently score above 75
Price targets
Analyst target
$19,000.00
+4439152.34%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
Price chart
Stock snapshot
Strengths
+ Revenue growth 58.60% QoQ
+ Debt/equity 0.25x — low leverage
Risks
- Piotroski 3/9 — weak financial health
- Altman Z -24.37 — distress zone
- Thin margins at 0.00%
- Negative free cash flow $-9.66M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $61.80M | $6.53M | $8.04M | $286000.00 | $286000.00 |
| Net income | $-71.67M | $23.92M | $-8.27M | $-429000.00 | $-429000.00 |
| EPS | — | — | — | — | $0.00 |
| Free cash flow | $-29.38M | $-35.83M | $-9.38M | $-9.66M | $-9.66M |
| Profit margin | -115.97% | 366.25% | -102.80% | -150.00% | — |
Peer comparison
Smart narrative
Redhill Biopharma Ltd trades at $0.43. Our Smart Value Score of 34/100 indicates the stock is weak. The company scores 3/9 on the Piotroski F-Score. With an Altman Z-Score of -24.37, it sits in the distress.
Frequently asked questions
What is Redhill Biopharma Ltd's stock price?
Redhill Biopharma Ltd (RDHL) trades at $0.43, on a P/S of 10.2x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Redhill Biopharma Ltd overvalued?
Redhill Biopharma Ltd carries a Smart Value Score of 34/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.
What is the price target of Redhill Biopharma Ltd (RDHL)?
The 12-month analyst consensus target is $19,000.00, about 4439152.3% above the current $0.43. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
Altman Z-Score?
Redhill Biopharma Ltd's Altman Z-Score is -24.37, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryDRUG MANUFACTURERS - SPECIALTY & GENERIC
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio10.21x
ROE-193.70%
Beta4.90
50D MA$0.58
200D MA$0.84
Shares out0.01B
Float0.00B
Short ratio—
Avg volume2.6M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—